ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.158,95
0,92%
S&P 500
5.158,12
0,59%
Dow Jones
38.754,21
0,20%
Euro vs US Dollar
1,07816
0,22%
Bitcoin
63.112,27
-1,39%
Registration Strip Icon for charts Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Xenon Pharmaceuticals Inc (XENE)

  7. Xenon Pharmaceuticals Inc (XENE) News

XENE Xenon Pharmaceuticals Inc

43,805
0,055 (0,13%)
Zuletzt aktualisiert: 16:55:24
Verzögert um 15 Minuten
Name Symbol Markt Aktientyp
Xenon Pharmaceuticals Inc XENE NASDAQ Common Stock
  Änderung Änderung % Aktuell Zeit
Upgrade Icon
0,055 0,13% 43,805 16:55:24
Handelsbeginn Niedrig Hoch Schlusskurs Handelsende
43,87 43,52 44,3672 43,75
more quote information »

Aktuelle News

Datum Zeit Quelle Überschrift
02.5.202422:01GLOBEXenon Pharmaceuticals Announces Conference Call and Webcast..
16.4.202414:30GLOBEXenon Pharmaceuticals Showcases XEN1101 at the American..
04.4.202422:01GLOBEXenon Pharmaceuticals to Present at the 23rd Annual Needham..
12.3.202421:01GLOBEXenon Pharmaceuticals to Present at Stifel 2024 Virtual CNS..
09.3.202400:47EDGAR2Form 144 - Report of proposed sale of securities
08.3.202423:31EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08.3.202423:28EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08.3.202423:27EDGAR2Form 8-K - Current report
08.3.202401:04EDGAR2Form 144 - Report of proposed sale of securities
08.3.202401:03EDGAR2Form 144 - Report of proposed sale of securities
05.3.202422:01GLOBEXenon Pharmaceuticals to Present at Leerink Partners Global..
29.2.202422:10EDGAR2Form 8-K - Current report
29.2.202422:01GLOBEXenon Pharmaceuticals Reports Fourth Quarter and Full Year..
22.2.202422:01GLOBEXenon Pharmaceuticals Announces Conference Call and Webcast..
14.2.202415:12EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
08.1.202414:00GLOBEXenon Pharmaceuticals Outlines Key Milestone Opportunities..
03.1.202414:30GLOBEXenon Pharmaceuticals to Present at the 42nd Annual J.P...
02.1.202422:41EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04.12.202322:16GLOBEXenon Pharmaceuticals Announces Closing of $345.0 Million..
02.12.202318:01GLOBEXenon Pharmaceuticals Provides Updates on Neurology Pipeline..
30.11.202322:18EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
30.11.202322:15EDGAR2Form 8-K - Current report
30.11.202304:51GLOBEXenon Pharmaceuticals Announces Pricing of Upsized $300.0..
29.11.202323:05EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
29.11.202322:03GLOBEXenon Pharmaceuticals Announces Proposed Public Offering
27.11.202313:03EDGAR2Form 8-K - Current report
27.11.202313:00GLOBEXenon Pharmaceuticals Announces Topline Results from Phase 2..
09.11.202322:06EDGAR2Form 8-K - Current report
09.11.202322:03GLOBEXenon Pharmaceuticals Provides Update on Partnered Program..
08.11.202322:36EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08.11.202322:11EDGAR2Form 8-K - Current report
08.11.202322:01GLOBEXenon Pharmaceuticals Reports Third Quarter 2023 Financial..
01.11.202321:01GLOBEXenon Pharmaceuticals Announces Conference Call and Webcast..
09.10.202322:15GLOBEXenon Pharmaceuticals Announces Publication of Results from..
06.10.202314:30GLOBEXenon Pharmaceuticals to Present at Jefferies Inaugural..
14.9.202322:01GLOBEXenon Pharmaceuticals to Present at TD Cowen’s 3rd Annual..
12.9.202322:30GLOBEXenon Pharmaceuticals Announces Upcoming Investor Webinar..
04.9.202314:30GLOBEXenon Pharmaceuticals Showcases XEN1101 Epilepsy Program at..
31.8.202322:01GLOBEXenon Pharmaceuticals to Present at the Wells Fargo 2023..
11.8.202301:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
11.8.202301:00EDGAR2Form 3 - Initial statement of beneficial ownership of..
11.8.202300:56EDGAR2Form 4 - Statement of changes in beneficial ownership of..
11.8.202300:40EDGAR2Form 3 - Initial statement of beneficial ownership of..
09.8.202322:38EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
09.8.202322:16EDGAR2Form 8-K - Current report
09.8.202322:01GLOBEXenon Pharmaceuticals Reports Second Quarter 2023 Financial..
08.8.202322:07EDGAR2Form 8-K - Current report
08.8.202322:01GLOBEXenon Pharmaceuticals Expands Leadership on its Board of..
02.8.202322:01GLOBEXenon Pharmaceuticals Announces Conference Call and Webcast..
06.6.202322:35GLOBEXenon Pharmaceuticals to Present at the Goldman Sachs 44th..

Kürzlich von Ihnen besucht

NASDAQ
XENE
Xenon Pharmaceuticals
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten